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This study examines the association between insulin resistance, schizophrenia polygenic risk, and
treatment outcomes in first-episode, antipsychotic-naive patients with schizophrenia.
Patients with schizophrenia show an increased risk of impaired glucose metabolism,  yet the mechanism
behind this association remains unknown. Multiple studies have attempted to identify the determinants of
insulin resistance (IR) in schizophrenia, with evidence suggesting that it cannot be fully explained by
disease duration, symptom severity, medication effects, obesity, or hormonal stress axis activation, and
other interacting factors are likely involved.  While family and genome-wide association studies have
suggested a shared genetic vulnerability between schizophrenia and abnormal glucose metabolism,  to our
knowledge, a direct link between schizophrenia genetic risk and insulin resistance has not been
investigated. Here, we examine the association between IR, schizophrenia polygenic risk, and treatment
outcomes in first-episode, antipsychotic-naive patients with schizophrenia and matched healthy individuals
while controlling for demographic, lifestyle, and clinical factors.
Methods
First-episode, antipsychotic-naive patients with schizophrenia and matched unaffected control individuals
(58 patients with schizophrenia and 58 control individuals; Table) were recruited at the University Hospital
Marqués de Valdecilla (Santander, Spain) as described previously.  The study procedures were approved
by the medical faculty ethical committee, and written informed consent was obtained from all study
participants. Schizophrenia polygenic risk scores (PRS) were calculated based on 108 genome-wide
significant schizophrenia loci  from the Illumina Infinium PsychArray Bead-Chip genotyping data
imputed using IMPUTE2/SHAPEIT. The updated Homeostasis Model Assessment (HOMA2)  was used
to infer IR, β cell function, and insulin sensitivity from clinical measurements of fasting serum glucose and
insulin levels. Switching antipsychotic medication at least once during the initial 12 months of treatment
was used as a heuristic long-term treatment outcome measure. All statistical tests were 2-sided and are
described in figure legends. A P value of less than .05 was considered significant. Analyses were
conducted in R, version 3.5.0 (R Foundation).
Results
Consistent with previous reports,  patients with schizophrenia showed increased baseline HOMA2-IR
(mean difference [MD] [SE], 0.68 [0.25]; P = .004), HOMA2 β-cell function (MD [SE], 32.2 [13.1]; P 
= .02), and fasting insulin levels (MD [SE], 5.5 [2.1] μIU/mL [to convert to picomoles per liter, multiply
by 6.945]; P = .004), whereas HOMA2 insulin sensitivity (MD [SE], −19.6 [15.5]; P = .20) and fasting
glucose levels (MD [SE], 0.6 [2.0] mg/dL [to convert to millimoles per liter, multiply by 0.0555]; P = .76)
did not differ significantly from control values (Table). After adjusting for covariates, HOMA2-IR
remained significantly increased in patients with schizophrenia (MD [SE], 0.82 [0.25]; P < .001, adjusted
for body mass index; Figure, A). The HOMA2-IR was positively associated with schizophrenia PRS in
patients with schizophrenia (β [SE], 3.74 [1.68]; P = .02, adjusted for age; Figure, B) but not in the control
group (adjusted β [SE], 0.29 [0.40]; P = .45), where body mass index was the most significant risk factor
(adjusted β [SE], 0.071 [0.018]; P < .001). Baseline HOMA2-IR was significantly associated with
switching antipsychotic medication during the initial 12 months of treatment, with an adjusted odds ratio
(OR) of 1.77 (95% CI, 1.10-3.52; P = .02, adjusted for ethnicity; Figure, C). Of the 41 patients for whom
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criteria for IR (≥25 μIU/mL)  required changing medication within the first year of treatment.
Schizophrenia PRS was not significantly associated with medication switching status (adjusted OR, 183;
95% CI, 0.48-504 931; P = .12).
Discussion
We report that schizophrenia polygenic risk is significantly associated with insulin resistance in first-
episode, antipsychotic-naive patients with schizophrenia independent from selected demographic, lifestyle,
and clinical factors. This result suggests that IR is a hallmark of schizophrenia rather than a secondary
effect of emerging symptoms and supports the hypothesis that multiple susceptibility genes might exert
pleiotropic effects cooccurring between the 2 conditions. Furthermore, the results indicate a potential
association of IR with diminished response to antipsychotic treatment. Hence, patients with schizophrenia
presenting with IR might constitute a distinct patient subgroup and require personalized treatment tailored
to this endophenotype.
Limitations
Limitations of this study include incomplete metadata for subsets of clinical variables and the fact that
although nonresponse was the primary factor influencing medication switching, other clinical variables,
such as adverse effects and treatment nonadherence, cannot be excluded in a minority of cases. Well-
powered pharmacogenomic studies and more specific assays, such as the oral glucose tolerance and
cortisol tests,  are required to further examine the association between IR, schizophrenia, and
antipsychotic treatment response, in addition to determining the effects of other lifestyle factors such as
diet and exercise.
References
1. Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. Impaired glucose homeostasis in
first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(3):261-
269. doi:10.1001/jamapsychiatry.2016.3803 [PMCID: PMC6352957] [PubMed: 28097367] [CrossRef:
10.1001/jamapsychiatry.2016.3803]
2. Chouinard VA, Henderson DC, Dalla Man C, et al. . Impaired insulin signaling in unaffected siblings
and patients with first-episode psychosis. Mol Psychiatry. 2018. doi:10.1038/s41380-018-0045-1
[PMCID: PMC6129440] [PubMed: 29523870] [CrossRef: 10.1038/s41380-018-0045-1]
3. Lago SG, Tomasik J, van Rees GF, et al. . Exploring the neuropsychiatric spectrum using high-content
functional analysis of single-cell signaling networks. Mol Psychiatry. 2018. doi:10.1038/s41380-018-
0123-4 [PubMed: 30038233] [CrossRef: 10.1038/s41380-018-0123-4]
4. Ripke S, Neale BM, Corvin A, et al. ; Schizophrenia Working Group of the Psychiatric Genomics
Consortium . Biological insights from 108 schizophrenia-associated genetic loci. Nature.
2014;511(7510):421-427. doi:10.1038/nature13595 [PMCID: PMC4112379] [PubMed: 25056061]
[CrossRef: 10.1038/nature13595]
5. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses
the computer program. Diabetes Care. 1998;21(12):2191-2192. doi:10.2337/diacare.21.12.2191 [PubMed:
9839117] [CrossRef: 10.2337/diacare.21.12.2191]
6. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 12th ed




14/7/2020 Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583823/?report=printable 4/10
14/7/2020 Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583823/?report=printable 5/10
Table.
Demographic and Clinical Data of Study Participants
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Abbreviations: %B, beta cell function (%); BMI, body mass index (calculated as weight in kilograms divided by
height in meters squared); BPRS, Brief Psychiatric Rating Scale; HOMA2, the updated Homeostasis Model
Assessment; IR, insulin resistance; NA, not applicable; PRS, schizophrenia polygenic risk score; SANS, Scale for the
Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; %S, insulin sensitivity
(%).
SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555; insulin to picomoles per liter,
multiply by 6.945.
Data were analyzed using t test for continuous variables and Fisher exact test or χ  test for categorical variables. P
values were obtained by permutation testing (N = 1000 permutations).
Significant (<.05) P value.







Control Schizophrenia       
Sex
Male 35 (60) 36 (62)
>.99 NA NA
Female 23 (40) 22 (38)
Age, mean (SD), y 31.8 (7.6) 29.5 (8.5) .15 NA NA
BMI, mean (SD) 24.4 (3.7) 23.0 (5.0) .07 NA NA
Race/ethnicity
White 58 (100) 52 (90)
.03 NA NAHispanic 0 (0) 5 (9)
Romani 0 (0) 1 (2)
Smoking
No 28 (48) 25 (43)
.73 NA NA
Yes 30 (52) 33 (57)
Alcohol
No 42 (72) 28 (48)
.02 NA NA
Yes 16 (28) 30 (52)
Cannabis
No 44 (76) 32 (55)
.04 NA NA
Yes 14 (24) 26 (45)
Family history of diabetes
No 3 (5) 26 (45)
.04 49 (84) 22 (38)
Yes 6 (10) 10 (17)
Family history of psychiatric
disease
No 58 (100) 45 (78)
<.001 NA NA
Yes 0 13 (22)
Previous psychiatric medication
No 58 (100) 45 (78)
<.001 NA NA
Yes 0 (0) 13 (22)
Age at onset of psychosis, mean
(SD), y
NA 28.4 (8.4)
NA NA 1 (2)
First antipsychotic
Aripiprazole NA 28 (48)
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Self-reported.
Assessed using the Comprehensive Assessment of Symptoms and History.
Antidepressant; mean (SD) duration, 7.8 (8.3) days.
Antipsychotic treatment was initiated after baseline data collection and used for determining switching medication
status in Figure, C.
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Figure.
Open in a separate window
Analysis of the Homeostasis Model Assessment of Insulin Resistance (HOMA2-IR) in First-Episode, Antipsychotic-
Naive Patients With Schizophrenia and Healthy Control Individuals.
A, Association of HOMA2-IR with clinical status. B, Association of HOMA2-IR with the 108 loci schizophrenia
polygenic risk score. C, Association of antipsychotic drug switching during the initial 12 months of treatment with
baseline HOMA2-IR. Plots show adjusted mean with standard error (A) and marginal effects with 95% confidence
intervals (B and C). Statistical tests included analysis of covariance (A) and multivariable linear (B) and logistic (C)
regression. Covariates were selected using bidirectional elimination and Bayesian information criterion from age, sex,
body mass index, race/ethnicity, smoking, alcohol consumption, cannabis use, and previous psychiatric medication (A-C);
baseline Brief Psychiatric Rating Scale, Scale for the Assessment of Positive Symptoms, and Scale for the Assessment of
Negative Symptoms scores (B; schizophrenia group); and the initial treatment drug (C). Only cases with complete data
were analyzed. P values were obtained by permutation testing (1000 permutations). P less than .05 was considered
significant. Numbers: A, 54 control individuals and 56 patients with schizophrenia; B, 53 control individuals and 49
patients with schizophrenia; C, 20 patients with schizophrenia with no drug switch and 21 patients with schizophrenia
with drug switch (13 owing to low efficacy, 5 owing to adverse effects, and 3 owing to noncompliance).
P < .001.a
b
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P < .05.b
